Center-Authored Papers

Filters: Author is Taplin, Mary-Ellen  [Clear All Filters]
2013
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P, Lin D, Taplin M-E, Balk S, Ellis W et al..  2013.  Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.. The Journal of steroid biochemistry and molecular biology. 138C:281-289. Abstract
2014
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S et al..  2014.  Enzalutamide in Metastatic Prostate Cancer before Chemotherapy.. The New England journal of medicine. Abstract
Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PFA, Mainwaring P, Hainsworth JD et al..  2014.  Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302).. European urology. Abstract
2015
Higano CS, Beer TM, Taplin M-E, Efstathiou E, Hirmand M, Forer D, Scher HI.  2015.  Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.. European urology. 68(5):795-801. Abstract
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin M-E, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT et al..  2015.  Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With . Clinical genitourinary cancer. 13(3):e191-8. Abstract
Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin M-E, Penning TM.  2015.  The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.. Chemico-biological interactions. 234:332-8. Abstract
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative clinical genomics of advanced prostate cancer.. Cell. 161(5):1215-28. Abstract
2016
Pritchard CC, Mateo J, Walsh MF, DeSarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.. The New England journal of medicine. 375(5):443-453. Abstract
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN et al..  2016.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W et al..  2016.  ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 22(14):3672-82. Abstract
Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin D, Sanda M et al..  2016.  Neoadjuvant Enzalutamide Prior to Prostatectomy.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Taplin M-E, McKay RR, Werner L, Mostaghel EA, Lis RT, Voznesensky O, Zhang Z, Marck B, Matsumoto AM, Domachevsky L et al..  2016.  A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
2017
Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck B, Sharifi N, Wright JL, Gulati R et al..  2017.  Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Zang T, Taplin M-E, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley G, Montgomery B, Balk SP, Mostaghel EA et al..  2017.  Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.. Endocrine-related cancer. 24(8):393-404. Abstract